Scientists at The Scripps Research Institute (TSRI) have achieved a major milestone toward designing a safe and effective vaccine to both treat heroin addiction and block lethal overdose of the drug.
Their research, published today in the journal Molecular Pharmaceutics, shows how a new anti-heroin formulation that is safe in animal models remains stable at room temperature for at least 30 days. As a result, the vaccine is close to being ready for human testing.
“The heroin vaccine is one step closer to clinical evaluation,” says Candy S. Hwang, PhD, first author of the study and a research associate at TSRI.
According to the National Institute on Drug Abuse, 15,446 Americans died from heroin overdose between 2000 and 2016, and the mortality rates are increasing. Heroin abuse has been further fueled by a rise in prescription opioid abuse—studies show that opioid pain reliever users are 40 times more likely to abuse heroin.
The first formulation of the heroin vaccine was developed in 2013 by a team led by Kim D. Janda, PhD, the Ely R. Callaway Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI. It has been shown to be effective—and safe—in both mouse and non-human primate models.
The vaccine works by training the immune system antibodies to recognize and bind to heroin molecules, blocking the drug from reaching the brain to cause a “high.” Researchers believe that blocking the high of heroin will help eliminate the motivation for many recovering addicts to relapse into drug use.
The heroin molecule does not naturally prompt an antibody response, so researchers attach it to a carrier protein that alerts the immune system to start making antibodies. Scientists also add an ingredient called an adjuvant to the vaccine, which boosts the immune response and makes the vaccine more effective.
Hwang says, “Our goal was to prepare a vaccine that could be advanced to clinical trials. As such, we were looking for the best combination of ‘hapten’ (the heroin molecule), carrier protein and adjuvant to keep the vaccine both stable for transport and storage but still efficacious.”
For the new study, the researchers investigated how 20 different carrier protein/adjuvant combinations worked, including shelf stability based on temperature and storage time and whether the formulation was a liquid or powder.
Their experiments in rodent models showed that the best vaccine formulation contained a carrier protein called tetanus toxoid (TT) and adjuvants called alum and CpG ODN. The discovery that alum worked best as an adjuvant was especially significant since alum is one of the few adjuvants used in vaccines already approved by the U.S. Food and Drug Administration. The researchers also found that there was no difference in how well it worked between the liquid and powder versions of this formulation.
Hwang notes that the best vaccine formulation showed protection against lethal doses of heroin. This is particularly important as many heroin addicts have succumb to overdose and death during their attempts to quit the drug.
With this new study, the researchers have shown that the vaccine is safe and effective in animal models, stable under clinical conditions and reliant on an already-approved adjuvant. The next step is to find a producer to make the vaccine on a large scale.
“We believe that a heroin vaccine would be tremendously beneficial for people who have a heroin substance use disorder but have found difficulty in trying to quit,” says Hwang.
Learn more: Heroin vaccine blocks lethal overdose
The Latest on: Heroin vaccine
- Live Attenuated Vaccines Market Revenue Predicted To Go Up at 10.7% Says Pfizer Inc., Sanofi Pasteur, Bayer Healthcare Till 2023 on November 13, 2018 at 4:55 am
Vaccines created by reducing the virulence of pathogens are ... toxin and linker technology to research and produce an antibody-drug conjugate (ADC) as a potential cancer therapy. Moreover, in July 20... […]
- Isothermal Boxes for Vaccines Market to Hold a High Potential for Growth by 2028 on November 8, 2018 at 6:27 pm
Valley Cottage, NY -- (SBWIRE) -- 11/08/2018 -- Future Market Insights (FMI) delivers key insights on the global isothermal boxes for vaccines market in its published report titled "Global Isothermal ... […]
- EU drug agency urges dengue vaccine approval amid concerns in PH on November 8, 2018 at 7:58 am
LONDON — Europe’s drug regulator has recommended approving the first vaccine for dengue despite concerns about the vaccine’s wide use and a lawsuit in the Philippines alleging that it was ... […]
- The Daily Biotech Pulse: Nantkwest Reports Positive Cancer Vaccine Trial Results, Sarepta Offering on November 8, 2018 at 4:10 am
Releasing the first human clinical trial results of its cancer vaccine, Nantkwest Inc (NASDAQ ... which was commercially sold in September following FDA approving the drug. The net loss per share narr... […]
- Drugs and vaccines from Sanofi on the fast track on November 7, 2018 at 11:58 pm
Six rare-disease drugs and new vaccines from the company made their debut at the expo ... Aubagio, the first new oral drug for the treatment of multiple sclerosis, a rare disease of the nervous system ... […]
- T Cells That Stay Put Could Be Key to a Better Salmonella Vaccine on November 7, 2018 at 5:27 am
25 a breakthrough in understanding which cells protect against Salmonella infection – a critical step in developing a more effective and safe vaccine against a bacterium that annually kills an estimat... […]
- What We're Reading: HPV Vaccine Use; $4 Million Drug; ACS Fundraising Concerns on November 6, 2018 at 6:52 am
A report from the President’s Cancer Panel has found that use of human papillomavirus (HPV) vaccines remain low, despite improvements; Novartis believes that its new gene therapy to treat spinal muscu... […]
- Classical Swine Fever Vaccines Market: Production, Revenue, Growth Rate, Price and Gross Margin on November 6, 2018 at 6:44 am
â Classical Swine Fever Vaccines Market report provides detail analysis that will enterprise your business to the next level, it contains overview including market demand, growth factors, current tren... […]
- BioNTech taps Drew Weissmann’s UPenn lab to expand into infectious disease mRNA vaccines on November 5, 2018 at 5:50 am
BioNTech has teamed up with the University of Pennsylvania to develop nucleoside-modified mRNA vaccines. The pact tasks Drew Weissmann’s UPenn lab with taking vaccines against up to 10 infectious dise... […]
- Pharma Giants Raise 2018 Profit Guidance On Third-Quarter Vaccine Boost on November 1, 2018 at 3:08 pm
... unit came from preventative drugs often administered to children and travel/endemic vaccines. Sales of Regeneron Pharmaceuticals (REGN)-partnered eczema drug Dupixent spiked 198.7% to about $261 m... […]
via Google News and Bing News